Index -
P/E -
EPS (ttm) -26.08
Insider Own 56.24%
Shs Outstand 5.75M
Perf Week -2.44%
Market Cap 60.14M
Forward P/E -
EPS next Y -2.46
Insider Trans 29.15%
Shs Float 4.70M
Perf Month 26.98%
Income -34.36M
PEG -
EPS next Q -0.67
Inst Own 12.04%
Short Float 0.93%
Perf Quarter 9.59%
Sales 0.00M
P/S -
EPS this Y 70.66%
Inst Trans 1.57%
Short Ratio 2.10
Perf Half Y 74.99%
Book/sh 1.42
P/B 3.95
EPS next Y -9.57%
ROA -132.51%
Short Interest 0.04M
Perf Year 73.37%
Cash/sh 1.05
P/C 5.35
EPS next 5Y -
ROE -155.72%
52W Range 1.75 - 8.59
Perf YTD 95.80%
Dividend Est. -
P/FCF -
EPS past 5Y 19.56%
ROI -421.20%
52W High -34.81%
Beta 1.31
Dividend TTM -
Quick Ratio 2.88
Sales past 5Y 0.00%
Gross Margin -
52W Low 220.00%
ATR (14) 0.40
Dividend Ex-Date -
Current Ratio 2.88
EPS Y/Y TTM -12.44%
Oper. Margin 0.00%
RSI (14) 62.26
Volatility 3.08% 9.38%
Employees 14
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 16.69
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q 84.94%
Payout -
Rel Volume 0.17
Prev Close 5.65
Sales Surprise -
EPS Surprise 11.75%
Sales Q/Q -
Earnings Mar 28 BMO
Avg Volume 20.74K
Price 5.60
SMA20 9.51%
SMA50 22.64%
SMA200 49.55%
Trades
Volume 3,585
Change -0.88%
May-07-24 08:00AM
Apr-24-24 08:00AM
Apr-10-24 03:30PM
Mar-28-24 11:53AM
07:00AM
08:00AM
Loading…
Mar-13-24 08:00AM
Feb-28-24 06:57PM
Feb-13-24 08:00AM
Feb-07-24 04:05PM
Jan-22-24 08:00AM
Dec-11-23 07:30AM
Nov-09-23 07:00AM
Nov-02-23 09:15AM
Sep-06-23 07:30AM
Aug-31-23 07:30AM
07:01AM
Loading…
Aug-11-23 07:01AM
Aug-10-23 04:05PM
06:24AM
Aug-09-23 07:30AM
06:26AM
Aug-08-23 06:28AM
Aug-07-23 06:35AM
Aug-04-23 07:14AM
Aug-03-23 07:15AM
Aug-02-23 07:52AM
Aug-01-23 06:51AM
Jul-31-23 06:44AM
Jul-28-23 07:58AM
Jul-27-23 07:10AM
Jul-26-23 01:12PM
07:16AM
Loading…
Jul-25-23 07:16AM
Jul-24-23 07:12AM
Jul-21-23 07:23AM
Jul-20-23 06:55AM
Jul-19-23 07:10AM
Jul-18-23 06:53AM
Jul-17-23 07:10AM
Jul-14-23 06:50AM
Jul-13-23 07:02AM
Jul-12-23 07:22AM
Jul-11-23 06:08AM
Jul-10-23 06:56AM
Jul-05-23 06:46AM
Jul-03-23 06:50AM
Jun-30-23 06:52AM
Jun-29-23 06:49AM
Jun-28-23 06:58AM
Jun-27-23 06:46AM
Jun-26-23 06:41AM
Jun-23-23 09:24AM
Jun-12-23 07:30AM
Jun-06-23 07:30AM
May-23-23 07:30AM
May-15-23 08:55AM
Mar-29-23 07:53PM
CalciMedica, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for life-threatening inflammatory diseases. The firm's product candidate Auxora helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Roberts Eric W CHIEF BUSINESS OFFICER Apr 02 '24 Buy 3.90 3,254 12,691 39,894 Apr 02 08:33 PM Roberts Eric W CHIEF BUSINESS OFFICER Apr 01 '24 Buy 3.90 746 2,909 36,640 Apr 02 08:33 PM MIDDLETON FRED A Director Jan 23 '24 Buy 3.70 679,384 2,515,080 946,744 Jan 25 08:00 PM Sanderling Venture Partners VI 10% Owner Jan 23 '24 Buy 3.70 436,028 1,614,176 727,433 Jan 25 08:00 PM Sanderling Venture Partners VI 10% Owner Jan 23 '24 Buy 3.70 243,356 900,904 946,744 Jan 25 08:00 PM WILSON ROBERT N Director Dec 11 '23 Buy 3.30 506 1,670 182,161 Dec 13 08:45 PM Leheny A. Rachel Chief Executive Officer Nov 07 '23 Buy 3.34 2,000 6,680 18,840 Nov 08 08:42 PM Leheny A. Rachel Chief Executive Officer Nov 06 '23 Buy 3.12 2,440 7,615 16,840 Nov 07 06:09 PM Roberts Eric W Chief Business Officer Nov 06 '23 Buy 3.12 2,400 7,488 35,894 Nov 08 08:41 PM Hebbar Sudarshan Chief Medical Officer Nov 03 '23 Buy 2.74 36,000 98,600 46,000 Nov 07 06:08 PM Roberts Eric W Chief Business Officer Nov 03 '23 Buy 2.83 11,249 31,846 33,494 Nov 07 08:42 PM Roberts Eric W Chief Business Officer Nov 03 '23 Buy 2.70 5,860 15,828 22,245 Nov 06 06:40 PM Leheny A. Rachel Chief Executive Officer Nov 03 '23 Buy 2.85 5,000 14,250 14,400 Nov 06 06:39 PM Roberts Eric W Chief Business Officer Nov 03 '23 Buy 2.77 3,700 10,249 20,287 Nov 07 08:42 PM Roberts Eric W Chief Business Officer Nov 03 '23 Buy 2.80 3,200 8,960 16,587 Nov 06 06:40 PM Roberts Eric W Chief Business Officer Aug 25 '23 Buy 3.18 736 2,340 5,000 Aug 29 07:34 PM Roberts Eric W Chief Business Officer Aug 22 '23 Buy 3.27 714 2,335 4,264 Aug 23 06:02 PM Roberts Eric W Chief Business Officer Aug 21 '23 Buy 3.25 1,750 5,688 3,550 Aug 23 06:02 PM Roberts Eric W Chief Business Officer Jun 26 '23 Buy 3.70 1,200 4,441 13,387 Jun 26 08:33 PM Roberts Eric W Chief Business Officer Jun 26 '23 Buy 3.53 200 706 16,385 Jun 26 08:33 PM Roberts Eric W Chief Business Officer Jun 23 '23 Buy 3.35 500 1,675 16,185 Jun 26 08:33 PM
Index -
P/E -
EPS (ttm) -0.93
Insider Own 11.04%
Shs Outstand 88.93M
Perf Week 1.85%
Market Cap 86.99M
Forward P/E -
EPS next Y -1.02
Insider Trans 0.14%
Shs Float 79.74M
Perf Month -1.97%
Income -82.59M
PEG -
EPS next Q -0.24
Inst Own 46.09%
Short Float 1.70%
Perf Quarter 4.35%
Sales 0.04M
P/S 2174.65
EPS this Y 2.76%
Inst Trans -1.70%
Short Ratio 3.18
Perf Half Y -1.39%
Book/sh 1.94
P/B 0.50
EPS next Y -12.95%
ROA -36.50%
Short Interest 1.36M
Perf Year -14.12%
Cash/sh 1.77
P/C 0.55
EPS next 5Y -
ROE -39.86%
52W Range 0.88 - 1.57
Perf YTD 0.83%
Dividend Est. -
P/FCF -
EPS past 5Y 8.31%
ROI -47.17%
52W High -38.18%
Beta 1.28
Dividend TTM -
Quick Ratio 8.61
Sales past 5Y 292.67%
Gross Margin 98.98%
52W Low 10.28%
ATR (14) 0.06
Dividend Ex-Date -
Current Ratio 8.61
EPS Y/Y TTM -146.35%
Oper. Margin -227407.32%
RSI (14) 49.97
Volatility 7.23% 5.84%
Employees 72
Debt/Eq 0.01
Sales Y/Y TTM -99.88%
Profit Margin -201443.90%
Recom 1.29
Target Price 7.00
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q -1.24%
Payout -
Rel Volume 0.28
Prev Close 1.01
Sales Surprise -100.00%
EPS Surprise -13.74%
Sales Q/Q -100.00%
Earnings May 01 BMO
Avg Volume 426.37K
Price 0.97
SMA20 3.52%
SMA50 -5.43%
SMA200 -3.87%
Trades
Volume 126,065
Change -3.91%
Date
Action
Analyst
Rating Change
Price Target Change
May-23-23 Initiated
Robert W. Baird
Outperform
$7
Sep-07-22 Initiated
CapitalOne
Overweight
$7
Apr-29-21 Initiated
Maxim Group
Buy
$20
Apr-23-21 Resumed
Cowen
Outperform
$10 → $18
Mar-31-21 Initiated
Wedbush
Outperform
$21
Mar-31-21 Initiated
Jefferies
Buy
$21
Feb-14-18 Downgrade
JP Morgan
Neutral → Underweight
Feb-02-18 Initiated
H.C. Wainwright
Buy
$10
Aug-09-16 Reiterated
FBR Capital
Mkt Perform
$9 → $8
Feb-23-16 Reiterated
FBR Capital
Mkt Perform
$14 → $10
Feb-23-16 Downgrade
Morgan Stanley
Equal-Weight → Underweight
Feb-23-16 Downgrade
Barclays
Overweight → Equal Weight
$12 → $6
Feb-22-16 Downgrade
Citigroup
Buy → Neutral
Dec-29-15 Downgrade
JP Morgan
Overweight → Neutral
$65 → $15
Dec-28-15 Reiterated
Piper Jaffray
Overweight
$63 → $10
Dec-28-15 Downgrade
FBR Capital
Outperform → Mkt Perform
$73 → $14
Dec-17-15 Initiated
UBS
Buy
$55
Oct-05-15 Downgrade
Morgan Stanley
Overweight → Equal-Weight
Sep-03-15 Initiated
Citigroup
Buy
Aug-18-15 Initiated
FBR Capital
Outperform
$73
Show Previous Ratings
May-02-24 10:23AM
03:09AM
May-01-24 11:58PM
(Thomson Reuters StreetEvents)
12:54PM
07:33AM
(Associated Press Finance)
07:00AM
Loading…
07:00AM
Apr-24-24 07:00AM
Apr-16-24 04:05PM
Mar-21-24 07:00AM
Mar-01-24 09:06AM
Feb-29-24 11:25PM
(Thomson Reuters StreetEvents) -7.26%
08:11AM
07:27AM
(Associated Press Finance)
07:00AM
Feb-27-24 07:00AM
07:00AM
Loading…
Feb-22-24 07:00AM
Dec-29-23 07:00AM
Dec-04-23 07:00AM
Nov-24-23 07:00AM
Nov-16-23 07:00AM
Nov-03-23 09:12AM
01:34AM
(Thomson Reuters StreetEvents)
Nov-02-23 10:08AM
07:10AM
(Associated Press Finance)
07:00AM
Oct-26-23 07:00AM
Oct-23-23 10:08AM
Sep-05-23 07:00AM
Aug-16-23 10:05AM
Aug-11-23 06:15AM
08:25AM
Loading…
Aug-03-23 08:25AM
07:19AM
(Associated Press Finance)
07:00AM
Jul-31-23 07:54AM
Jul-30-23 02:17PM
Jul-28-23 04:19PM
Jul-27-23 10:53AM
07:00AM
06:00AM
Jul-11-23 08:53PM
Jun-28-23 02:58PM
(American City Business Journals)
Jun-27-23 04:05PM
Jun-01-23 08:04PM
May-31-23 04:01PM
May-25-23 07:00AM
May-05-23 06:11AM
May-04-23 08:25AM
07:17AM
07:00AM
Apr-27-23 07:00AM
Apr-18-23 04:01PM
Mar-29-23 10:13AM
09:35AM
Mar-06-23 05:51AM
Mar-03-23 06:57PM
Mar-02-23 10:10PM
(Thomson Reuters StreetEvents) +6.29%
07:00AM
Feb-28-23 04:05PM
Feb-23-23 07:00AM
Feb-17-23 09:04AM
Feb-13-23 05:55PM
Feb-07-23 01:51PM
Feb-02-23 02:19PM
Jan-19-23 10:49AM
Jan-05-23 07:00AM
Dec-27-22 02:53PM
(American City Business Journals) -6.52%
Dec-12-22 01:41PM
(American City Business Journals)
Dec-08-22 05:00PM
Nov-29-22 12:00PM
Nov-10-22 04:30PM
09:00AM
Nov-07-22 06:06AM
Nov-04-22 12:27PM
(American City Business Journals)
07:46AM
Nov-03-22 08:15AM
07:00AM
Nov-01-22 10:01AM
Oct-27-22 04:30PM
10:02AM
Oct-26-22 11:52AM
Sep-27-22 09:59PM
(American City Business Journals)
02:52PM
(American City Business Journals)
10:13AM
Sep-26-22 04:05PM
Sep-10-22 09:16AM
Sep-06-22 07:00AM
Sep-01-22 08:48AM
Aug-30-22 02:17PM
(American City Business Journals)
Aug-29-22 10:45AM
Aug-17-22 09:29AM
Aug-09-22 04:00AM
Aug-08-22 04:01PM
07:00AM
Aug-02-22 07:00AM
Aug-01-22 04:01PM
Jul-25-22 04:30PM
09:42AM
Jul-16-22 09:45AM
Jun-24-22 03:08PM
(American City Business Journals) +13.19%
10:37AM
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Jakeman David VP OF FINANCE AND ACCOUNTING Feb 14 '24 Sale 1.04 2,660 2,777 141,232 Feb 16 08:00 PM LaSpaluto Michelle CHIEF FINANCIAL OFFICER Feb 14 '24 Sale 1.04 1,940 2,023 110,999 Feb 16 08:01 PM Andriole Michael T. PRESIDENT AND CEO Feb 14 '24 Sale 1.04 1,744 1,809 447,021 Feb 16 08:02 PM MIDDLETON FRED A Director Nov 17 '23 Buy 0.96 17,295 16,522 100,000 Nov 20 03:28 PM MIDDLETON FRED A Director Nov 10 '23 Buy 0.92 2,705 2,489 82,705 Nov 13 04:39 PM Jakeman David VP of Finance and Accounting Sep 28 '23 Sale 0.99 3,610 3,584 133,142 Sep 28 04:17 PM MIDDLETON FRED A Director Sep 25 '23 Buy 0.98 20,000 19,636 80,000 Sep 26 03:58 PM Andriole Michael T. Chief Business Officer and CFO May 18 '23 Buy 1.14 51,700 59,150 357,015 May 19 11:41 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite